Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PARM1 antisense RNA 1 (PARM1-AS1) is *presumed to be a long non-coding RNA* (lncRNA) transcribed antisense to the PARM1 gene. Antisense lncRNAs can regulate the expression of their sense partner genes or exert regulatory functions via diverse mechanisms, including chromatin remodeling, transcription interference, or RNA duplex formation[3]. As of the present review, there is *no experimental evidence or peer-reviewed publication discussing the specific characteristics, biological functions, disease relevance, or therapeutic interest in PARM1-AS1*. The gene it is antisense to, PARM1 (prostate androgen-regulated mucin-like protein 1), is a membrane-associated mucin family protein potentially implicated in oncogenic processes[1][2], but **PARM1-AS1** itself is not documented as a protein, receptor, enzyme, transporter, or other canonical drug target. Absence of mention in scientific reporting suggests it may be a predicted, putative, or poorly annotated transcript.\n\n**Key Insights and Limitations:**\n- Many human lncRNAs, especially antisense species, remain poorly characterized and may be annotated in genomic databases without any experimental validation or known biological roles. \n- While antisense RNAs can theoretically affect gene regulation by acting in cis or trans[3], PARM1-AS1 lacks any such studied or reported activity. \n- There is no evidence of PARM1-AS1 being a drug target, disease biomarker, or having roles in human pathophysiology.\n\nIf your query was meant to refer to the protein "PARM1" (rather than the antisense RNA), please clarify, as that is a mucin family protein with some reported functions and disease links[1][2]. For the antisense RNA "PARM1-AS1," the above limitations and absence of evidence apply.
none (no drugs targeting this molecule, thus no mechanism of action)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PARM1 antisense RNA 1 (PARM1-AS1).